The Global Andersen Tawil Syndrome Treatment Industry is expected to develop at an unprecedented rate, reaching a projected milestone of US$ 4.2 billion by 2033 and an estimated worth of US$ 1.9 billion by 2023, according to a recent analysis by Future Market Insights (FMI). It is anticipated that the market would grow at a strong 8.26% Compound Annual Growth Rate (CAGR).
The Andersen Tawil Syndrome Treatment Market has experienced remarkable growth, which can be ascribed to multiple factors such as increased government support, incentives offered to pharmaceutical companies, increased public awareness among individuals and social groups, and improved physician communication in the quest for effective treatment solutions for uncommon illnesses.
One of the pivotal contributors to this growth is the increase in facilities for patients, coupled with a rise in incentives for research. Non-profit organizations dedicated to promoting health and treating rare diseases have played a crucial role in encouraging research efforts, further propelling market expansion.
Request a Sample of this Report Now! https://www.futuremarketinsights.com/reports/sample/rep-gb-16357
However, low prevalence of the Andersen-Tawil syndrome and the dearth of awareness remains a key problem hurting market players. High risk of misdiagnosis and undiagnosed cases continue as key issues that restrain industry’s growth. Further, High costs associated to rare disease research will hold back innovations and growth prospects which will hinder growth.
Few other factors hold back growth of the global market, such as the challenges in the research and development, delay in diagnosis thereby delaying the treatment, limitations concerning expertise, characteristic dearth of attractiveness from an economic standpoint, which eventually has resulted in the lack of commercial interest for private investors, lack of regulatory framework in developing economies coupled with lack of skilled healthcare personnel.
Global Andersen Tawil Syndrome Treatment Industry Key Takeaways
- Increasing focus of the government to prioritize drugs for the treatment of rare diseases are expected to propel growth
- Increasing participation of organizations to support the treatment and to create awareness is also anticipated to drive growth of the market.
- Growth in R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to aid in market expansion.
- North America is expected to dominate the market of Andersen Tawil syndrome.
- South Asia is projected to witness fastest growth during the forecast period.
- Type 1 Andersen Tawil Syndrome is projected to dominate the market with 59% market share by 2033.
“Increased government funding efforts aimed towards improving diagnostic procedures is anticipated to generate lucrative prospects for the participants in the Andersen-Tawil syndrome market. Non-profit organizations are playing key roles in raising awareness positively influencing market developments”, comments an FMI analyst.
Competitive Landscape
Key players in the Andersen Tawil Syndrome Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc., and Pfizer Inc.
Request For the Complete Report Methodology Now https://www.futuremarketinsights.com/request-report-methodology/rep-gb-16357
Some recent developments in the Global Andersen Tawil Syndrome Treatment Industry are:
- In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag to gain the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
- In December 2016, Strongbridge Biopharma plc has acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of the agreement, Taro Pharmaceutical Industries Ltd to receive an upfront payment of USD 8.50 mm and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of U.S. rights expands the company’s rare disease portfolio to include neuromuscular diseases.
More Valuable Insights
Future Market Insights, in its new offering, presents an unbiased analysis of the Bullous Keratopathy market, presenting historical analysis from 2017 to 2022 and forecast statistics for the period of 2023-2033.
The study reveals essential insights based on Disease type (Type 1, Type 2) By Drug class (Carbonic Anhydrate Inhibitors, Acetazolamide, Dichlorpenamide, Antiarrhythmic Drugs, Amiodarone, Flecainide, Beta-Blockers, Atenolol) By Distribution channel (Hospital Pharmacies, Retail pharmacies, Online Pharmacies) and by region (North America, Latin America, Europe, South Asia, East Asia, Oceania MEA)
About the Healthcare Division at Future Market Insights
The healthcare team at Future Market Insights offers expert analysis, time-efficient research, and strategic recommendations to provide authentic insights and accurate results to help clients worldwide. With a repertoire of over 100+ reports and 1 million+ data points, the team has been analyzing the industry lucidly in 50+ countries for over a decade. The team provides a brief analysis of key trends including competitive landscape, profit margin, and research development efforts.
Key Segments Profiled in the Global Andersen Tawil Syndrome Treatment Industry Survey
Disease Type:
- Type 1
- Type 2
Drug Class:
- Carbonic Anhydrate Inhibitors
- Acetazolamide
- Dichloropenamide
- Antiarrhythmic Drugs
- Amiodarone
- Flecainide
- Beta-Blockers
- Atenolol
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Author
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Nandini Singh Sawlani
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
